{"id":"ibrutinib-maintenance","safety":{"commonSideEffects":[{"rate":"40–50%","effect":"Diarrhea"},{"rate":"30–40%","effect":"Fatigue"},{"rate":"20–30%","effect":"Nausea"},{"rate":"20–30%","effect":"Bruising/bleeding"},{"rate":"15–25%","effect":"Infection"},{"rate":"5–10%","effect":"Atrial fibrillation"},{"rate":"10–15%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibrutinib covalently binds to BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, it prevents B-cell activation, proliferation, and migration, leading to reduced tumor cell survival in B-cell malignancies. In maintenance therapy, continued BTK inhibition helps prevent disease relapse and progression.","oneSentence":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, reducing their proliferation and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:24.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL) — maintenance therapy"},{"name":"Mantle cell lymphoma (MCL) — maintenance therapy"},{"name":"Waldenstrom macroglobulinemia — maintenance therapy"}]},"trialDetails":[{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT03697512","phase":"PHASE2","title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-09-27","conditions":"Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":175},{"nctId":"NCT03708003","phase":"PHASE2","title":"Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2019-03-11","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia","enrollment":30},{"nctId":"NCT03731234","phase":"PHASE2","title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-07-02","conditions":"DLBCL","enrollment":75},{"nctId":"NCT03620903","phase":"PHASE2","title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian Buske","startDate":"2019-09-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":53},{"nctId":"NCT02558816","phase":"PHASE1, PHASE2","title":"A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2015-10-14","conditions":"Mantle Cell Lymphoma","enrollment":48},{"nctId":"NCT02388048","phase":"PHASE2","title":"Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2015-10","conditions":"Leukemia, Lymphoblastic, Chronic","enrollment":19},{"nctId":"NCT02692248","phase":"PHASE2","title":"Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-04-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":64},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT02997761","phase":"PHASE2","title":"Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Brian Jonas","startDate":"2017-06-27","conditions":"Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive","enrollment":20},{"nctId":"NCT02451111","phase":"PHASE2","title":"Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2015-11-06","conditions":"Follicular Lymphoma","enrollment":190},{"nctId":"NCT02242097","phase":"PHASE2","title":"Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2015-01-12","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT03689894","phase":"PHASE1, PHASE2","title":"Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2019-04-11","conditions":"Chronic Graft-versus-host-disease","enrollment":2},{"nctId":"NCT03267186","phase":"PHASE2","title":"Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant","status":"COMPLETED","sponsor":"Andrew Rezvani","startDate":"2017-09-12","conditions":"Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT03121534","phase":"PHASE2","title":"Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-22","conditions":"Hematopoietic/Lymphoid Cancer, Richter's Transformation","enrollment":9},{"nctId":"NCT02013128","phase":"PHASE1, PHASE2","title":"Ublituximab + Ibrutinib in Select B-cell Malignancies","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2014-01-06","conditions":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":66},{"nctId":"NCT03226301","phase":"PHASE2","title":"A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2017-06-23","conditions":"Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission","enrollment":230},{"nctId":"NCT02623010","phase":"PHASE2","title":"Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2016-10","conditions":"Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT02356458","phase":"PHASE1, PHASE2","title":"Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2015-08-31","conditions":"Mantle Cell Lymphoma","enrollment":58},{"nctId":"NCT04994626","phase":"PHASE2","title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-10-01","conditions":"DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation","enrollment":20},{"nctId":"NCT04992377","phase":"PHASE2","title":"R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-08-30","conditions":"Richter Transformation","enrollment":30},{"nctId":"NCT02689869","phase":"PHASE2","title":"Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-04","conditions":"Indolent Non-Hodgkin Lymphoma","enrollment":98},{"nctId":"NCT02689141","phase":"PHASE2","title":"Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2016-02-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":66},{"nctId":"NCT01752426","phase":"PHASE1, PHASE2","title":"Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-17","conditions":"Leukemia","enrollment":30},{"nctId":"NCT02006485","phase":"PHASE1","title":"Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2013-12-13","conditions":"Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma","enrollment":160},{"nctId":"NCT04066920","phase":"PHASE2","title":"IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL","status":"UNKNOWN","sponsor":"Deok-Hwan Yang","startDate":"2019-10-01","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT03980002","phase":"PHASE2","title":"A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-05-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT02345863","phase":"PHASE2","title":"Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2015-01-16","conditions":"Chronic Lymphocytic Leucemia","enrollment":66},{"nctId":"NCT02635074","phase":"PHASE1","title":"Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Steven E. Coutre","startDate":"2016-11","conditions":"Recurrent Adult Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870},{"nctId":"NCT02955628","phase":"PHASE2","title":"RICE-ibrutinib in Relapsed DLBCL","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2016-12-13","conditions":"Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Imbruvica"],"phase":"phase_3","status":"active","brandName":"Ibrutinib (Maintenance)","genericName":"Ibrutinib (Maintenance)","companyName":"Prof. Dr. M. Dreyling (co-chairman)","companyId":"prof-dr-m-dreyling-co-chairman","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, reducing their proliferation and survival. Used for Chronic lymphocytic leukemia (CLL) — maintenance therapy, Mantle cell lymphoma (MCL) — maintenance therapy, Waldenstrom macroglobulinemia — maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}